Free Trial

Abbott Laboratories (ABT) Stock Price, News & Analysis

Abbott Laboratories logo
$132.30 -1.01 (-0.76%)
Closing price 10/10/2025 03:59 PM Eastern
Extended Trading
$131.94 -0.36 (-0.27%)
As of 10/10/2025 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Abbott Laboratories Stock (NYSE:ABT)

Advanced

Key Stats

Today's Range
$132.05
$134.50
50-Day Range
$129.37
$136.82
52-Week Range
$110.86
$141.23
Volume
5.65 million shs
Average Volume
5.80 million shs
Market Capitalization
$230.26 billion
P/E Ratio
16.58
Dividend Yield
1.78%
Price Target
$146.17
Consensus Rating
Moderate Buy

Company Overview

Abbott Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
99th Percentile Overall Score

ABT MarketRank™: 

Abbott Laboratories scored higher than 99% of companies evaluated by MarketBeat, and ranked 11th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Abbott Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 16 buy ratings, 4 hold ratings, and no sell ratings.

  • Upside Potential

    Abbott Laboratories has a consensus price target of $146.17, representing about 10.5% upside from its current price of $132.30.

  • Amount of Analyst Coverage

    Abbott Laboratories has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Abbott Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for Abbott Laboratories are expected to grow by 11.48% in the coming year, from $5.14 to $5.73 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Abbott Laboratories is 16.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 230.98.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Abbott Laboratories is 16.58, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.27.

  • Price to Earnings Growth Ratio

    Abbott Laboratories has a PEG Ratio of 2.53. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Abbott Laboratories has a P/B Ratio of 4.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Abbott Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    1.04% of the float of Abbott Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Abbott Laboratories has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Abbott Laboratories has recently increased by 1.80%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Abbott Laboratories pays a meaningful dividend of 1.77%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Abbott Laboratories has been increasing its dividend for 54 years.

  • Dividend Coverage

    The dividend payout ratio of Abbott Laboratories is 29.57%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Abbott Laboratories will have a dividend payout ratio of 41.19% next year. This indicates that Abbott Laboratories will be able to sustain or increase its dividend.

  • Read more about Abbott Laboratories' dividend.
  • Percentage of Shares Shorted

    1.04% of the float of Abbott Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Abbott Laboratories has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Abbott Laboratories has recently increased by 1.80%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Abbott Laboratories has a news sentiment score of 1.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 55 news articles for Abbott Laboratories this week, compared to 33 articles on an average week.
  • Search Interest

    48 people have searched for ABT on MarketBeat in the last 30 days. This is an increase of 26% compared to the previous 30 days.
  • MarketBeat Follows

    21 people have added Abbott Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 110% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Abbott Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $746,753.00 in company stock.

  • Percentage Held by Insiders

    Only 0.46% of the stock of Abbott Laboratories is held by insiders.

  • Percentage Held by Institutions

    75.18% of the stock of Abbott Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Abbott Laboratories' insider trading history.
Receive ABT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abbott Laboratories and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABT Stock News Headlines

URGENT: The Market's 3 Red Flags Are Flashing
The warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.tc pixel
UBS Reaffirms Their Buy Rating on Abbott Laboratories (ABT)
See More Headlines

ABT Stock Analysis - Frequently Asked Questions

Abbott Laboratories' stock was trading at $113.11 at the beginning of the year. Since then, ABT shares have increased by 17.0% and is now trading at $132.30.

Abbott Laboratories (NYSE:ABT) posted its quarterly earnings results on Thursday, July, 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories's quarterly revenue was up 7.4% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of Abbott Laboratories: Cephea Valve Technologies, Alere, St. Jude Medical, Kalila Medical, Tendyne Holdings Inc., Veropharm, Topera Inc., and more.

Top institutional shareholders of Abbott Laboratories include Bartlett & CO. Wealth Management LLC (0.06%), Voya Investment Management LLC (0.05%), Czech National Bank (0.03%) and Gradient Investments LLC (0.02%). Insiders that own company stock include Daniel J Starks, Robert B Ford, Jr Robert E Funck, Jr Robert E Funck, Daniel Gesua Sive Salvadori, John F Ginascol, Andrea F Wainer, Lisa D Earnhardt, Randel William Woodgrift, Philip P Boudreau, Julie L Tyler, Eric Shroff and John A Jr Mccoy.
View institutional ownership trends
.

Shares of ABT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Abbott Laboratories investors own include JPMorgan Chase & Co. (JPM), Chevron (CVX), NVIDIA (NVDA), Predictive Oncology (POAI), Bank of America (BAC), Meta Platforms (META) and AbbVie (ABBV).

Company Calendar

Record date for 8/15 Dividend
7/15/2025
Ex-Dividend for 8/15 Dividend
7/15/2025
Last Earnings
7/17/2025
Dividend Payable
8/15/2025
Today
10/11/2025
Record date for 11/17 Dividend
10/15/2025
Ex-Dividend for 11/17 Dividend
10/15/2025
Next Earnings (Estimated)
10/15/2025
Dividend Payable
11/17/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Health Care Equipment
Current Symbol
NYSE:ABT
CIK
1800
Employees
114,000
Year Founded
1894

Price Target and Rating

High Price Target
$160.00
Low Price Target
$137.00
Potential Upside/Downside
+10.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
22 Analysts

Profitability

EPS (Trailing Twelve Months)
$7.98
Trailing P/E Ratio
16.58
Forward P/E Ratio
25.74
P/E Growth
2.53
Net Income
$13.40 billion
Net Margins
32.43%
Pretax Margin
18.32%
Return on Equity
18.32%
Return on Assets
10.71%

Debt

Debt-to-Equity Ratio
0.25
Current Ratio
1.82
Quick Ratio
1.30

Sales & Book Value

Annual Sales
$41.95 billion
Price / Sales
5.49
Cash Flow
$6.53 per share
Price / Cash Flow
20.25
Book Value
$27.62 per share
Price / Book
4.79

Miscellaneous

Outstanding Shares
1,740,460,000
Free Float
1,732,453,000
Market Cap
$230.26 billion
Optionable
Optionable
Beta
0.69

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NYSE:ABT) was last updated on 10/11/2025 by MarketBeat.com Staff
From Our Partners